scholarly journals Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions

2019 ◽  
Vol 26 (8) ◽  
pp. 849-850
Author(s):  
Hiroki Ishihara ◽  
Tsunenori Kondo ◽  
Toshio Takagi ◽  
Kazuhiko Yoshida ◽  
Masayoshi Okumi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Case Series ◽  
Developing Brain

scholarly journals Metastatic Renal Cell Carcinoma to the Sinonasal Cavity: A Case Series

2013 ◽  
Vol 74 (02) ◽  
pp. 067-072 ◽  
Author(s):  
Peter Sadow ◽  
Derrick Lin ◽  
Stacey Gray ◽  
Aaron Remenschneider
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Case Series

scholarly journals Differences Between Patients (Pts) with Metastatic Renal Cell Carcinoma (Mrcc) Who Develop Brain Metastases (Bm) Versus Those Who Do Not

2014 ◽  
Vol 25 ◽  
pp. iv286
Author(s):  
L. Derosa ◽  
G. Le Teuff ◽  
L. Albiges Sauvin ◽  
Y. Loriot ◽  
C. Massard ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

scholarly journals Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
Nicole M. Agostino ◽  
Rebecca Gingrich ◽  
Joseph J. Drabick
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Single Agent ◽  
Interleukin 2 ◽  
Case Series ◽  
Growth Factor Receptor ◽  
Mtor Inhibitors ◽  
Heavily Pretreated

There are now a variety of therapies approved for the treatment of metastatic renal cell carcinoma (RCC). These include the immunotherapeutics, alfa-interferon, and interleukin-2, and agents that target the vascular endothelial growth factor receptor (VEGFR) via its tyrosine kinase, such as sorafenib, sunitinib, and pazopanib, or the mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus. Bevacizumab, a monoclonal antibody directed against the ligand, VEGF, has shown activity against RCC as a single agent in patients who had failed prior cytokine therapy and as first line therapy in combination with interferon. The activity of bevacizumab in patients who had received and failed prior therapy has not been described. We report our experience in 4 patients with metastatic RCC who had failed prior cytokine, TKI, and mTOR inhibitors who were treated with bevacizumab as single agent therapy. These heavily pretreated patients sustained very prolonged periods of stable disease (median of 12 months) with very little toxicity and excellent quality of life. The activity of this agent in patients who had failed prior therapies directed against the VEGFR and mTOR suggests that therapy targeting the ligand, VEGF, is still a viable approach in these patients and deserves further study.

scholarly journals Sunitinib in metastatic renal cell carcinoma patients with brain metastases

Cancer ◽  
2010 ◽  
Vol 117 (3) ◽  
pp. 501-509 ◽  
Author(s):  
Martin E. Gore ◽  
Subramanian Hariharan ◽  
Camillo Porta ◽  
Sergio Bracarda ◽  
Robert Hawkins ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy

2018 ◽  
Vol 104 (6) ◽  
pp. 444-450 ◽  
Author(s):  
Ibrahim Yildiz ◽  
Ahmet Bilici ◽  
Nuri Karadurmuş ◽  
Leyla Ozer ◽  
Deniz Tural ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Median Time ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Initial Diagnosis ◽  
Histological Subtype ◽  
Systemic Metastasis

Background: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and methods: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. Results: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line suni-tinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months; p = 0.001), histological subtype (non-CC; p<0.05) and number of BMs (>2; p<0.05) were significantly associated with OS in multivariate analysis. There were no cases of toxic death. One mRCC patient with BMs (1.7%) experienced treatment-related cerebral necrosis. All other toxicities included those commonly observed with VEGF-TKI therapy. Conclusions: The time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months), a non-CC histological subtype, and a greater number of BMs (>2) were independent risk factors for a poor prognosis.

Sign in / Sign up

Export Citation Format

Share Document